Literature DB >> 28000477

Probiotic: effectiveness nutrition in cancer treatment and prevention.

Débora Mara Kich1, Angélica Vincenzi, Fernanda Majolo, Claucia Fernanda Volken de Souza, Márcia Inês Goettert.   

Abstract

Among the neoplasias, colorectal cancer is one of the leading causes of cancer death in men and women. The increasing incidence of this type of cancer is due to the increase in the population's life expectancy, by the increase in chronic inflammatory bowel diseases, primarily ulcerative colitis and Crohn's disease, and the change in eating habits. The American Cancer Society (2011) shows that diet might be responsible for approximately 30% of cancer cases in developed countries, moreover when considering only colorectal cancer, the number can reach 30% to 50%. Probiotics are effective in the prevention and treatment of many bowel diseases as inflammatory bowel disease (IBD), diarrhea, irritable bowel syndrome, gluten intolerance, gastroenteritis, Helicobacter pyloriinfection, and colon cancer. Classical examples are strains from the Lactobacillus, and Bifidobacteriumgenus that have probiotic proprieties with a potential use in the prophylaxis, as well as in the treatment of a variety of gastrointestinal tract disorders. Researchers are focusing on extremely important studies regarding the possibility of using probiotics to promote a balanced microbiota composition, and a sufficient immunological surveillance system as a way to prevent cancer. Considering the fact that the human intestines host 100 trillion bacteria, including more than 1,000 species, there is still need to perform more in depth investigations in order to find probiotics with potential to prevent, and treat cancerous diseases, adding a very promising effect to this already successful panorama. This revision aims to conduct a review of the most recent studies correlating probiotics and its cancer preventing and treatment potential.

Entities:  

Keywords:  Colorectal cancer. Inflammatory bowel disease. Probiotics. Intestinal microbiota. Immune system.

Mesh:

Year:  2016        PMID: 28000477     DOI: 10.20960/nh.806

Source DB:  PubMed          Journal:  Nutr Hosp        ISSN: 0212-1611            Impact factor:   1.057


  6 in total

Review 1.  Emerging role of human microbiome in cancer development and response to therapy: special focus on intestinal microflora.

Authors:  Hourieh Sadrekarimi; Zhanna R Gardanova; Morteza Bakhshesh; Farnoosh Ebrahimzadeh; Amirhossein Fakhre Yaseri; Lakshmi Thangavelu; Zahra Hasanpoor; Firoozeh Abolhasani Zadeh; Mohammad Saeed Kahrizi
Journal:  J Transl Med       Date:  2022-07-06       Impact factor: 8.440

Review 2.  Precision Nutrition for Targeting Lipid Metabolism in Colorectal Cancer.

Authors:  Cristina Aguirre-Portolés; Lara P Fernández; Ana Ramírez de Molina
Journal:  Nutrients       Date:  2017-09-28       Impact factor: 5.717

Review 3.  Effects of therapeutic probiotics on modulation of microRNAs.

Authors:  Amirhossein Davoodvandi; Havva Marzban; Pouya Goleij; Amirhossein Sahebkar; Korosh Morshedi; Samaneh Rezaei; Maryam Mahjoubin-Tehran; Hossein Tarrahimofrad; Michael R Hamblin; Hamed Mirzaei
Journal:  Cell Commun Signal       Date:  2021-01-11       Impact factor: 5.712

4.  Probiotic Properties and Immunomodulatory Activity of Lactobacillus Strains Isolated from Dairy Products.

Authors:  Luz María Rocha-Ramírez; Ulises Hernández-Chiñas; Silvia Selene Moreno-Guerrero; Arturo Ramírez-Pacheco; Carlos A Eslava
Journal:  Microorganisms       Date:  2021-04-13

Review 5.  The Challenge of ICIs Resistance in Solid Tumours: Could Microbiota and Its Diversity Be Our Secret Weapon?

Authors:  Michela Roberto; Catia Carconi; Micaela Cerreti; Francesca Matilde Schipilliti; Andrea Botticelli; Federica Mazzuca; Paolo Marchetti
Journal:  Front Immunol       Date:  2021-08-20       Impact factor: 7.561

6.  Overexpression of luxS Promotes Stress Resistance and Biofilm Formation of Lactobacillus paraplantarum L-ZS9 by Regulating the Expression of Multiple Genes.

Authors:  Lei Liu; Ruiyun Wu; Jinlan Zhang; Pinglan Li
Journal:  Front Microbiol       Date:  2018-11-12       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.